FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

(E	AND EXCHANGE	COMMISSIC
Machinatan	D C 20540	

OMB APPROVAL

- 1											
	OMB Number:	3235-0287									
	Estimated average burden										
	hours per response	. 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

.(0). 0.	ee instruction	10.																				
Name and Address of Reporting Person* Howell Michael						2. Issuer Name and Ticker or Trading Symbol Zura Bio Ltd [ZURA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
nowell	Michae	<u>I</u>			1					,					Direc	tor	10% Own		ner			
																Officer (give title below)			Other (specify below)			
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 04/22/2024									See Remarks							
C/O ZURA BIO LTD																						
1489 WEST WARM SPRINGS ROAD, #110																						
(Ott)						4. If Amendment, Date of Original Filed (Month/Day/Year) 04/24/2024										6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	DCON N	1 7 0	001	4	"	,									Form	filed b	y One Re	porting	Perso	n		
HENDERSON NV 89014			4											Form filed by More than One Reporting								
(City)	(5	tate) (3	Zin)												Person							
(Oity)	(City) (State) (Zip)																					
		Table	1 - 1	Non-Deriva	tive	Secu	rities	Ac	cquir	ed, D	ispos	ed o	f, or I	Benefic	ially Own	ed						
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Yea					ar) l	2A. Deemed Execution Date if any (Month/Day/Yea		,	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an 5)				Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I)		7. Nature of Indirect Beneficial Ownership			
							F	Code V A		A		(A) or Price		Reported Transaction(s)		(Instr. 4)		(Instr. 4)				
									Code	ľ	Amount		(D)	Price	(Instr. 3 and 4)							
Class A ordinary shares 04/22/2024				4			A ⁽¹⁾		7,987	(2)	A	\$3.13	7,987		I		By corporation ⁽³⁾					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
		141	0.0	(e.g., pu																		
1. Title of Derivative Conversion or Exercise Price of Derivative Security					Transaction of Code (Instr. Deriva		vative irities ired r osed) r. 3, 4	e (Mo	oiration	ay/Year) Securitie Underlyi Derivativ		unt of rities erlying rative rity (Instr.	8. Price of Derivative Security (Instr. 5)	deriva Secur Benet Owne Follow Repor	ities Forricially Dire or In (I) (II) (II) (II) (II) (II) (II) (I		ership : t (D) direct str. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code V		(A)	(D)	Date D) Exercisal			ration	Title	Amount or Number of Shares									

Explanation of Responses:

- 1. On April 24, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'A' instead of transaction code 'P'
- 2. These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Mountaineer Biosciences, Inc. ("Mountaineer") at a purchase price of \$3.13 per share.
- 3. These shares are beneficially owned by Mountaineer. The Reporting Person is the Co-Founder of Mountaineer and, as such, has the power to vote and dispose of the ordinary shares held by Mountaineer. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

09/06/2024 /s/ Michael Howell

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.